Nutcracker Therapeutics and Elegen launched a pilot program demonstrating the industry's first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). This approach eliminates bacterial cell use in DNA template production, mitigating contamination risks and accelerating GMP RNA production with a turnaround time of approximately three weeks. The platform promises enhanced speed, scalability, and reliability, addressing major bottlenecks in PCT manufacturing processes and improving accessibility for patients requiring timely therapies.